Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
Related news for (ASND)
- Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
- Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
- New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
